BioStock: Positive preclinical results for Curasight in lung cancer

Biotech company Curasight recently announced positive preclinical results for uTREAT in the treatment of non-small cell lung cancer, showing that uTREAT effectively inhibits tumor growth. These findings comes on the heels of recent positive preclinical results in the treatment of glioblastoma, reinforcing the hypothesis that uTREAT is not cancer type specific, but has the potential to treat a broader spectrum of solid tumors.

Read the interview with Curasights CEO Ulrich Krasilnikoff at biostock.se:

https://www.biostock.se/en/2023/10/positive-preclinical-results-for-curasight-in-lung-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se